Northwest Biotherapeutics, Inc. (NWBO) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Bethesda, MD, United States. The current CEO is Linda F. Powers.
NWBO has IPO date of 2001-12-14, 25 full-time employees, listed on the Other OTC, a market capitalization of $308.14M.
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
